In recent years, significant advancements have been made in understanding the pathogenesis of Alzheimer’s disease (AD) through the accumulation and monitoring of biomarkers, shedding light on the accumulation and prevalence of AD pathology. Blood biomarkers used to predict the pathology of AD are believed to form the basis for future-generation approaches, focusing on the detection and management of risk before the onset of neurodegenerative processes, and paving the way for proactive interventions.
Additionally, looking to the past is important to comprehend the present and gain insight into the future. Currently, the exaggerated expectations associated with the development of drug therapies for AD, targeting Aβ accumulation, pathological tau, and neurodegeneration (ATN classification system) with symptomatic-based pleiotropic effects, are reminiscent of the process in the 1990s….
